EPISODE 79: The Future of Osteoporosis Research: SABRE, AI, and the Next Era of Bone Health
Dr. Mary Bouxsein, Professor, Harvard Medical School
On this episode of Bone Talk, BHOF CEO Claire Gill is joined by Dr. Mary Bouxsein, Professor at Harvard Medical School and a leading researcher in bone health and biomechanics, to discuss groundbreaking advances that could transform osteoporosis care. Their conversation explores how the SABRE initiative is reshaping osteoporosis drug development, the growing role of artificial intelligence in fracture prediction and screening, and why greater awareness and participation in research are essential to improving bone health outcomes for millions of people.
Key Takeaways
SABRE Could Accelerate New Osteoporosis Treatments: One of the most significant developments in osteoporosis research is SABRE (Study to Advance Bone Mineral Density as a Regulatory Endpoint). Historically, clinical trials for osteoporosis therapies had to wait for fractures to occur before proving a treatment's effectiveness. SABRE demonstrated that changes in bone mineral density measured by DEXA scans can reliably predict fracture risk reduction, creating a pathway for faster, more efficient clinical trials and potentially bringing new therapies to patients sooner.
Collaboration Across Industry Made a Landmark Achievement Possible: The SABRE project required more than a decade of work and unprecedented cooperation among researchers, pharmaceutical companies, government organizations, and nonprofit partners. By analyzing data from more than 160,000 participants across 52 osteoporosis clinical trials, researchers were able to build the evidence needed to support regulatory change. The project highlights what can happen when organizations work together for the benefit of patients and the future of the field.
Artificial Intelligence Is Expanding Opportunities for Early Detection: Dr. Bouxsein discusses how AI is beginning to transform bone health by identifying osteoporosis risk using medical images that were originally taken for other reasons. Technologies that analyze routine X-rays and CT scans may help detect patients at risk for low bone density long before a fracture occurs. These innovations could improve access to screening, especially in communities where DEXA scanners are limited or unavailable.
Diversity and Transparency Must Remain Priorities in AI Development: While AI offers tremendous promise, both Claire and Dr. Bouxsein emphasize the importance of ensuring that algorithms are trained using diverse populations. Without representative data, AI models risk perpetuating existing healthcare disparities. Researchers, clinicians, regulators, and patient advocates all have a role to play in making sure future technologies serve everyone effectively and equitably.
Awareness and Advocacy Are Driving a New Era in Bone Health: The conversation closes on a hopeful note, highlighting growing public awareness around women's health and menopause, and the opportunity to connect those conversations to bone health. Dr. Bouxsein believes this increased attention can help drive earlier prevention, better education, greater patient engagement, and ultimately improved outcomes for people living with osteoporosis and low bone mass.
As Claire and Dr. Bouxsein make clear, the future of osteoporosis care is being shaped by innovation, collaboration, and patient advocacy. From the groundbreaking work of SABRE to the emerging possibilities of artificial intelligence, the field is moving toward faster treatment development, better screening tools, and more personalized care. With continued research and greater awareness, the next decade holds tremendous promise for improving bone health and reducing fracture risk for millions of people worldwide.
